Phase III study of tivantinib in hepatocellular carcinoma continues
22 March 2016 | By Victoria White
ArQule and Daiichi Sankyo today announced that the independent DMC has determined that the METIV-HCC will continue to its final analysis...
List view / Grid view
22 March 2016 | By Victoria White
ArQule and Daiichi Sankyo today announced that the independent DMC has determined that the METIV-HCC will continue to its final analysis...
2 February 2016 | By Victoria White
Daiichi Sankyo has announced that it will share its clinical trial data to qualified researchers through the clinicalstudydatarequest.com system...
10 November 2015 | By Victoria White
The SMC also announced positive recommendations for Roche’s Avastin (bevacizumab) and Daiichi Sankyo’s Lixiana (edoxaban)...
3 November 2015 | By Victoria White
The Breakthrough Therapy Designation was granted based on results from an extension cohort of a Phase 1 study that assessed the safety and efficacy of pexidartinib...
30 October 2015 | By Victoria White
CL-108 is being developed as a treatment for moderate to severe pain and the prevention of opioid-induced nausea and vomiting (OINV)...
29 October 2015 | By Victoria White
To mark its support for World Stroke Day, Daiichi Sankyo has initiated a campaign that highlights stroke risks associated with cardiovascular diseases...
19 October 2015 | By Victoria White
Daiichi Sankyo has said that it will reorganise its US commercial operations from a maturing primary care product portfolio to a differentiated specialty portfolio...
13 October 2015 | By Daiichi Sankyo
Daiichi Sankyo has teamed up with World Thrombosis Day to promote awareness of thrombosis, its causes, risk factors, and signs and symptoms...
23 September 2015 | By Victoria White
NICE has issued its final recommendation for edoxaban to help prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation...
15 September 2015 | By Victoria White
The agreement is in line with the Daiichi Sankyo R&D strategy to expand its portfolio in the prevention and treatment of thrombosis...
26 August 2015 | By Victoria White
NICE has recommended once-daily edoxaban for the treatment and prevention of recurrent DVT and pulmonary embolism, saying the drug is cost-effective for the NHS...
24 August 2015 | By Victoria White
ETNA registries have commenced in Europe to collect a robust set of information on how once-daily edoxaban is being used in real world settings...
30 July 2015 | By Victoria White
Clinical trial results demonstrate that PLX3397 induced prolonged tumour regressions in most patients with tenosynovial giant cell tumour (TGCT)...
13 July 2015 | By Victoria White
NICE has recommended anti-blood clotting drug Lixiana as an option for treating and preventing the recurrence of potentially fatal blood clots...
10 July 2015 | By Victoria White
Edoxaban, a new blood-thinning drug therapy to help prevent stroke in patients with non-valvular atrial fibrillation, has been launched in the UK...